Answers are grounded in this paper and cite their sources.
Since the outbreak of coronavirus disease 2019 (COVID-19) in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone rapid evolution, resulting in substantial changes in transmissibility, pathogenicity, and immune escape potential. This ongoing viral diversification has largely undermined the protective efficacy of existing vaccines and neutralizing antibodies, posing major challenges to the clinical management of COVID-19 1 , 2 . Several monoclonal antibodies previously granted emergency use authorization by the U.S. Food and Drug Administration for the treatment of mild-to-moderate COVID-19 have now been restricted or withdrawn due to their markedly reduced activity against emerging variants, particularly those from the Omicron lineage. Among these, the Omicron subvariant JN.1 has attracted global attention and was designated a variant of interest by the World Health Organization in December 2023, shortly after its emergence 3 . Owing to its extensive antigenic divergence, the JN.1 variant demonstrates broad resistance to class 1, 2, and 3 receptor-binding domain (RBD)-targeting antibodies 4 . Its enhanced immune evasion has contributed to its rapid rise as a predominant circulating strain worldwide, highlighting the urgent need for next-generation antiviral strategies capable of retaining efficacy against highly evolved SARS-CoV-2 variants.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: